AVAGARD Drug Patent Profile

Which patents cover Avagard, and when can generic versions of Avagard launch?

Avagard is a drug marketed by 3M and is included in one NDA.

The generic ingredient in AVAGARD is alcohol; chlorhexidine gluconate. There are forty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the alcohol; chlorhexidine gluconate profile page.

Summary for AVAGARD

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	53
Clinical Trials:	2
DailyMed Link:	AVAGARD at DailyMed

Recent Clinical Trials for AVAGARD

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Universidad Autonoma de Nuevo Leon	N/A
3M	Phase 4

See all AVAGARD clinical trials

Pharmacology for AVAGARD

Physiological Effect

Decreased Cell Wall Integrity

US Patents and Regulatory Information for AVAGARD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
3m	AVAGARD	alcohol; chlorhexidine gluconate	SOLUTION;TOPICAL	021074-001	Jun 7, 2001		OTC	Yes	Yes

Expired US Patents for AVAGARD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
3m	AVAGARD	alcohol; chlorhexidine gluconate	SOLUTION;TOPICAL	021074-001	Jun 7, 2001	7,081,246
3m	AVAGARD	alcohol; chlorhexidine gluconate	SOLUTION;TOPICAL	021074-001	Jun 7, 2001	5,897,031
3m	AVAGARD	alcohol; chlorhexidine gluconate	SOLUTION;TOPICAL	021074-001	Jun 7, 2001	7,566,460
3m	AVAGARD	alcohol; chlorhexidine gluconate	SOLUTION;TOPICAL	021074-001	Jun 7, 2001	6,623,744
3m	AVAGARD	alcohol; chlorhexidine gluconate	SOLUTION;TOPICAL	021074-001	Jun 7, 2001	6,534,069

International Patents for AVAGARD

See the table below for patents covering AVAGARD around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0906049	DISTRIBUTEUR POUR LIQUIDES ANTIMICROBIENS (DISPENSER FOR ANTIMICROBIAL LIQUIDS)
Canada	2257592	DISTRIBUTEUR POUR LIQUIDES ANTIMICROBIENS (DISPENSER FOR ANTIMICROBIAL LIQUIDS)
Australia	715468
European Patent Office	0833606	COMPOSITIONS HYDRO-ALCOOLIQUES STABLES (STABLE HYDROALCOHOLIC COMPOSITIONS)
Japan	3811742

AVAGARD Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Avagard Hand Antiseptic

Introduction

Avagard, a surgical and healthcare personnel hand antiseptic, is a critical product in the healthcare industry, particularly in surgical and clinical settings. This article will delve into the market dynamics and financial trajectory of Avagard, highlighting its effectiveness, market position, and financial implications.

Product Efficacy and Regulatory Compliance

Avagard, formulated with Chlorhexidine Gluconate 1% Solution and Ethyl Alcohol 61% w/w, has demonstrated robust antimicrobial efficacy. It meets or exceeds FDA standards for surgical scrub products, showing rapid bactericidal activity against a broad spectrum of microorganisms, including antibiotic-resistant strains like MRSA and MRSE[1].

Market Position

Avagard stands out in the market due to its superior performance compared to other antiseptic products. It significantly outperforms competitors like Betadine® and Hibiclens® in terms of bacterial log reductions and persistence of antimicrobial activity. This superiority is crucial in maintaining skin health and preventing infections, making Avagard a preferred choice among healthcare professionals[1].

Financial Implications

The financial trajectory of Avagard is influenced by several factors, including its market demand, pricing, and competition.

Cost-Effectiveness

Avagard's effectiveness in reducing bacterial load and its long-lasting antimicrobial activity contribute to its cost-effectiveness. By reducing the need for repeated applications and minimizing the risk of infections, Avagard can help healthcare facilities save on overall infection control costs[1].

Market Competition

The market for surgical hand antiseptics is competitive, with products like Betadine® and Hibiclens®. However, Avagard's superior performance and skin-friendly properties give it a competitive edge. This edge can translate into higher market share and revenue, despite potential pricing pressures from competitors[1].

Pricing and Revenue

While specific pricing details for Avagard are not publicly available, its market position suggests that it could command a premium price due to its superior efficacy and skin care benefits. The revenue generated from Avagard sales would be significant, given its widespread use in surgical and healthcare settings.

Impact on Skin Health

Avagard is not only effective against microorganisms but also gentle on the skin. It prevents dry, cracked skin and reduces erythema (redness) and roughness, making it a preferred choice for healthcare personnel who need to maintain hand hygiene frequently[1].

Regulatory Environment

Avagard complies with CDC, FDA, and AORN criteria for surgical scrub selection, ensuring it meets the highest standards of safety and efficacy. This compliance is crucial for maintaining market trust and regulatory approval[1].

User Satisfaction

User satisfaction is high with Avagard due to its moisturizing properties and minimal irritation. This satisfaction can lead to increased loyalty and repeat purchases, contributing positively to the product's financial trajectory[1].

Market Trends and Future Outlook

The demand for effective hand antiseptics is likely to remain high due to the ongoing need for infection control in healthcare settings. Avagard's position as a leader in this market segment suggests a stable or growing financial trajectory.

Key Takeaways

• Superior Efficacy: Avagard outperforms competitors in antimicrobial activity and persistence.
• Cost-Effectiveness: Reduces overall infection control costs and minimizes the need for repeated applications.
• Market Position: Preferred choice due to its skin-friendly properties and compliance with regulatory standards.
• Financial Trajectory: Likely to command a premium price and generate significant revenue.
• User Satisfaction: High satisfaction due to minimal irritation and moisturizing properties.

FAQs

Q: What are the key ingredients in Avagard hand antiseptic? A: Avagard contains Chlorhexidine Gluconate 1% Solution and Ethyl Alcohol 61% w/w[1].

Q: How does Avagard compare to other antiseptic products like Betadine® and Hibiclens®? A: Avagard significantly outperforms these products in terms of bacterial log reductions and persistence of antimicrobial activity[1].

Q: What are the benefits of using Avagard for skin health? A: Avagard prevents dry, cracked skin, reduces erythema, and feels less rough compared to other antiseptics[1].

Q: Does Avagard meet regulatory standards? A: Yes, Avagard meets CDC, FDA, and AORN criteria for surgical scrub selection[1].

Q: What is the expected financial trajectory for Avagard? A: Given its superior efficacy and market position, Avagard is likely to maintain a stable or growing financial trajectory.

Sources

1. 3M: Considerations for Use: Avagard Hand Prep.
2. Avalere: Manufacturer Learnings from the First Round of Negotiated MFPs.
3. Avalere: CMS Selects First 10 Drugs for Medicare Negotiation.
4. FDA: Center for Drug Evaluation and Research.
5. PubMed: Impact of financial medication assistance on medication adherence.